IN8BIO, INC. Lease, Cost
IN8BIO, INC. (INAB) reported Lease, Cost of $328.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- IN8BIO, INC. lease, cost for the quarter ending 2026-06-30 was $328.00K, a 70.77% decline year-over-year.
- IN8BIO, INC. lease, cost for the quarter ending 2026-03-31 was $389.00K, a 41.94% decline year-over-year.
- IN8BIO, INC. lease, cost for the quarter ending 2025-12-31 was $280.00K, a 59.24% decline year-over-year.
- IN8BIO, INC. lease, cost for the quarter ending 2025-09-30 was $956.00K, a 44.41% increase year-over-year.
- IN8BIO, INC. lease, cost for fiscal 2025 was $2.36M, a 10.27% decline from fiscal 2024.
- IN8BIO, INC. lease, cost for fiscal 2024 was $2.63M, a 4.23% decline from fiscal 2023.
- IN8BIO, INC. lease, cost for fiscal 2023 was $2.74M, a 120.40% increase from fiscal 2022.
- IN8BIO, INC. lease, cost for fiscal 2022 was $1.25M, a 8.66% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $328.00K 10-Q · filed 2026-08-06 | $717.00K 10-Q · filed 2026-08-06 | $997.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.95M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $389.00K 10-Q · filed 2026-05-07 | $669.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.63M derived: sum of 3 quarters · filed 2026-05-07 | $2.75M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $280.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.24M derived: sum of 2 quarters · filed 2026-03-12 | $2.36M derived: sum of 3 quarters · filed 2026-08-06 | $2.36M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $956.00K 10-Q · filed 2025-11-06 | $2.08M derived: sum of 2 quarters · filed 2026-08-06 | $2.08M 10-Q · filed 2025-11-06 | $3.44M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.12M 10-Q · filed 2026-08-06 | $1.79M 10-Q · filed 2026-08-06 | $2.48M derived: sum of 3 quarters · filed 2026-08-06 | $3.14M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $670.00K 10-Q · filed 2026-05-07 | $1.36M derived: sum of 2 quarters · filed 2026-05-07 | $2.02M derived: sum of 3 quarters · filed 2026-05-07 | $2.66M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $687.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.35M derived: sum of 2 quarters · filed 2026-03-12 | $1.99M derived: sum of 3 quarters · filed 2026-03-12 | $2.63M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $662.00K 10-Q · filed 2025-11-06 | $1.30M derived: sum of 2 quarters · filed 2025-11-06 | $1.94M 10-Q · filed 2025-11-06 | $2.64M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $637.00K 10-Q · filed 2025-08-07 | $1.28M 10-Q · filed 2025-08-07 | $1.98M derived: sum of 3 quarters · filed 2025-08-07 | $2.68M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $642.00K 10-Q · filed 2025-05-07 | $1.34M derived: sum of 2 quarters · filed 2025-05-07 | $2.04M derived: sum of 3 quarters · filed 2025-05-07 | $2.76M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.40M derived: sum of 2 quarters · filed 2025-03-13 | $2.12M derived: sum of 3 quarters · filed 2025-03-13 | $2.74M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $697.00K 10-Q · filed 2024-11-12 | $1.42M derived: sum of 2 quarters · filed 2024-11-12 | $2.04M 10-Q · filed 2024-11-12 | $1.93M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $722.00K 10-Q · filed 2024-08-08 | $1.35M 10-Q · filed 2024-08-08 | $1.23M derived: sum of 3 quarters · filed 2024-08-08 | $1.64M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $380.00K 10-Q · filed 2024-05-09 | $625.00K 10-Q · filed 2023-05-12 | $507.00K derived: sum of 2 quarters · filed 2024-05-09 | $920.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $540.00K derived: sum of 2 quarters · filed 2024-03-14 | $865.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.25M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $413.00K 10-Q · filed 2023-11-09 | $738.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.12M 10-Q · filed 2023-11-09 | $1.49M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $325.00K 10-Q · filed 2023-08-10 | $705.00K 10-Q · filed 2023-08-10 | $1.07M derived: sum of 3 quarters · filed 2023-08-10 | $1.42M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $380.00K 10-Q · filed 2023-05-12 | $749.00K derived: sum of 2 quarters · filed 2023-05-12 | $1.09M derived: sum of 3 quarters · filed 2023-05-12 | $1.44M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $369.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $713.00K derived: sum of 2 quarters · filed 2023-03-30 | $1.06M derived: sum of 3 quarters · filed 2023-03-30 | $1.36M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $344.00K 10-Q · filed 2022-11-10 | $694.00K derived: sum of 2 quarters · filed 2022-11-10 | $994.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $350.00K 10-Q · filed 2022-08-12 | $650.00K 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $301.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |